Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer - Gilde Healthcare

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer

July 2, 2019

IRVINE, Calif., /PRNewswire/ — Inari Medical, Inc. announced today that the company has appointed Thomas M. Tu, M.D. as Chief Medical Officer.

Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism (PE). He was the lead author in the publication of the FLARE trial that resulted in FDA clearance of the FlowTriever device for PE. “I am excited to join Inari Medical, which is poised to revolutionize treatment of pulmonary embolism and deep venous thrombosis,” said Dr. Tu. Prior to Inari, Dr. Tu was in practice in Louisville, Kentucky for 16 years. He served as Director of the Cardiac Catheterization Laboratory at Baptist Health Louisville, where he led the TAVR, PE, and CTO programs.

Dr. Tu is formerly the chairman of the Emerging Leader Mentorship program, a joint venture among SCAI, ACC, and CRF. He is also the former chairman of the SCAI-PAC. He is currently interested in new device development and healthcare transformation.

“Tom brings deep clinical and advocacy experience to Inari Medical,” said Bill Hoffman, CEO of Inari. “As we continue to execute our plan to produce and publish clinical data, expand our portfolio of venous disease treatment solutions, and train many more physician users, Tom’s expertise and perspective will be invaluable.”

Dr. Tu is a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. He is board-certified in cardiology, interventional cardiology, and is fellowship-trained in peripheral vascular intervention.

 

About Inari Medical, Inc.

Inari Medical, Inc. is a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism. Inari is focused on solutions that enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs. Inari has developed two novel mechanical thrombectomy technology platforms. The FlowTriever System has FDA clearance for the treatment of pulmonary embolism. The ClotTriever System has FDA clearance for thrombectomy in the peripheral vessels. Inari was founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator. The company is backed by Gilde Healthcare (www.gildehealthcare.com), Versant Ventures (www.versantventures.com) and U.S. Venture Partners (www.usvp.com).  For more information, please visit www.inarimedical.com.

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare IV is supported by the European Recovery Program – EIF facility.

Company contact

Inari Medical

Tara Dunn, Vice President Clinical Affairs
tarad@inarimedical.com

Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher...
November 20, 2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Gilde Healthcare Venture&Growth VI closes at its hard cap with €740 million from a balanced mix of international investors Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by...
November 15, 2023

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy...
October 17, 2023